EDAP TMS Reports Record Q1 HIFU Revenue Growth, Reaffirming 2026 Guidance

summarizeSummary

EDAP TMS SA announced strong first-quarter 2026 financial results, driven by record 78% year-over-year growth in HIFU revenue and significant increases in U.S. procedures and system shipments, while reaffirming its full-year guidance.

check_boxKey Events

• Record HIFU Revenue Growth

  The company reported $11.6 million in HIFU revenue for Q1 2026, representing a 78% increase year-over-year, marking the seventh consecutive quarter of growth in this core business segment.

• Strong Operational Metrics

  U.S. Focal One procedure volumes grew 53% year-over-year, and Focal One system shipments increased by 83% year-over-year, demonstrating strong momentum in the core business.

• Improved Gross Profit Margin

  Gross profit margin on net sales improved to 45.7% in Q1 2026, up from 42.0% in the same period last year, primarily due to a favorable product-mix shift and better absorption of fixed costs.

• Reaffirmed 2026 Financial Guidance

  EDAP TMS SA reiterated its full-year guidance, expecting core HIFU business revenue to be in the range of $50.0 million to $54.0 million, representing 34% to 45% year-over-year growth.

auto_awesomeAnalysis

This earnings report highlights robust operational performance in EDAP TMS SA's core High-Intensity Focused Ultrasound (HIFU) business, with substantial revenue growth and improved gross margins. This strong performance is particularly significant given the company's previously disclosed 'going concern' warning and recent efforts to authorize capital raising, suggesting progress in its path to sustainability. While the company reported increased net losses and a declining cash balance, the positive trends in its high-growth segment and reaffirmed guidance provide a strong counter-signal. Investors should monitor continued HIFU segment growth and cash management in future quarters.